MedPath

JENNIFER MITCHELL

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (100.0%)

Oxytocin on Approach Bias and Craving

Phase 2
Withdrawn
Conditions
Alcohol Use Disorder
Interventions
Drug: Placebo
First Posted Date
2019-03-07
Last Posted Date
2022-06-06
Lead Sponsor
Jennifer Mitchell
Registration Number
NCT03865615
Locations
🇺🇸

University of California, San Francisco, Berkeley, California, United States

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

Phase 2
Completed
Conditions
Alcohol Use Disorder
Anxiety Disorders
Stress Disorders, Post-Traumatic
Substance Use Disorders
Interventions
Drug: Placebo
First Posted Date
2016-04-19
Last Posted Date
2020-10-19
Lead Sponsor
Jennifer Mitchell
Target Recruit Count
63
Registration Number
NCT02742532
Locations
🇺🇸

Naval Medical Center San Diego, San Diego, California, United States

Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users

Phase 2
Completed
Conditions
Alcohol Abuse
Impulsive Behavior
Interventions
Drug: Placebo
First Posted Date
2016-04-15
Last Posted Date
2020-09-21
Lead Sponsor
Jennifer Mitchell
Target Recruit Count
62
Registration Number
NCT02740582
Locations
🇺🇸

University of California, Berkeley, Berkeley, California, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.